Increased drug consumption and surge in clinical trials and outsourcing trends in pharma are significantly driving the pharmacovigilance industry demand. Pharmacovigilance involves the monitoring and evaluation of drug-related side effects, ensuring patient safety across all phases of the drug lifecycle. With growing pharmaceutical and biotechnology R&D activity, the need for efficient drug surveillance systems has significantly increased.
Furthermore, the expansion of clinical trials globally, particularly in emerging markets, is contributing to the demand for robust PV services. As a result, the pharmacovigilance market is experiencing steady growth, backed by healthcare providers’ and regulators’ focus on minimizing risks associated with drug use.
Leading market players are closely tracking the latest pharmacovigilance market trends and integrating advanced technologies such as artificial intelligence, machine learning, and automation into their safety monitoring systems. These technologies are enabling faster detection and reporting of adverse events, reducing manual workload, and improving overall data accuracy.
Moreover, key players are also expanding their service offerings to include end-to-end PV solutions-from clinical development to post-marketing surveillance-to meet the diverse needs of global pharmaceutical companies.
Pharmacovigilance is the science and activity connected with the detection, evaluation, assessment, and prevention of adverse or any other inappropriate drug-related issues. It serves as an essential element to promote the safety of medicinal products when they reach the marketplace. Pharmacovigilance aids the regulatory agencies and pharmaceutical industry to take timely steps for public protection by tracking and reviewing adverse drug reactions (ADRs).
The increasing focus on drug safety, tight regulatory compliance, and heightened public awareness have amplified the importance of pharmacovigilance over the years. The increase in international clinical trials, post-marketing surveillance, and technology solutions like AI and big data analytics is revolutionizing pharmacovigilance practices. Consequently, there is a heightened need for pharmacovigilance services, particularly in outsourcing models that are cost-efficient and scalable. The industry is influenced by both regulatory requirements and the pharmaceutical sector's desire to be in compliance while ensuring patient safety across a product's life cycle.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
The growing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases has led to higher drug consumption, increasing the risk of adverse drug reactions (ADRs). This calls for effective pharmacovigilance systems to track and maintain patient safety. For instance, in August 2024, a cross-sectional study conducted at Teaching Hospital Karapitiya in Sri Lanka found a 6.2% prevalence of ADRs among hospitalized patients, with diabetes mellitus significantly associated with ADR occurrence.
At the same time, upsurge in clinical trials, especially in emerging economies such as India, is reforming drug development. India's clinical trials market is growing significantly with a mixed patient pool and cost-effective opportunities, with revenues expected to surpass USD 2 billion in 2030. This growth creates huge safety data to be meticulously observed, again highlighting the importance of pharmacovigilance.
Thus, the dual forces of increased drug consumption and the proliferation of clinical trials are propelling the pharmacovigilance market growth. Additionally, growing emphasis on patient safety and regulatory compliance underscores the critical role of pharmacovigilance in the healthcare industry, further fueling market expansion in the coming years.
Pharmacovigilance (PV) practices are being significantly influenced by the increasing trend of outsourcing in the pharma industry. With an attempt to maximize operational efficiency and cut costs, most pharmaceutical companies are increasingly going for outsourcing pharmacovigilance services to dedicated service providers and Contract Research Organizations (CROs). Such an operational shift enables firms to focus on core competencies like drug discovery and development, and outsource safety monitoring and regulatory compliance to partners capable of doing it.
Outsourcing pharmacovigilance practices has several benefits, such as gaining access to state-of-the-art technology and highly qualified human resources that might not be present within the organization. CROs typically have sophisticated data management and analysis software, which allows them to effectively identify and evaluate ADRs and report them to regulatory bodies in a timely manner. Additionally, outsourcing enables the conduct of global pharmacovigilance operations. CROs operate in several regions and have in-depth understanding of multiple regulatory settings, which promotes compliance and expedites the process of safety review.
For instance, in 2024, TFS emphasized the adoption of automation and AI/ML in PV activities. Their survey indicated a projected increase in automation usage from 20% to over 60% in case processing within a year. Additionally, 40% of organizations outsourced more than 60% of their case processing tasks, highlighting the reliance on CROs for technological capabilities.
The Contract Outsourcing Delivery Mode holds a strong position in the global pharmacovigilance market due to several key advantages. It allows pharmaceutical companies to access skilled professionals and advanced technologies without the high cost of maintaining large in-house teams. CROs offer dedicated, full-time pharmacovigilance experts and high-quality data analysis capabilities.
Outsourcing also offers flexibility in operations. With growing drug portfolios and heightened regulatory requirements, CROs can expand and reallocate resources rapidly to respond to fluctuating workloads. This responsiveness facilitates quicker reactions to changing safety requirements.
Lastly, adherence to global regulatory standards continues to be an important aspect of pharmacovigilance operations. Contract Research Organizations (CROs) follow globally harmonized processes, which significantly reduce the risk of regulatory non-compliance. The combination of specialized expertise, operational scalability, cost-effectiveness, and strong regulatory alignment continues to make the Contract Outsourcing Delivery Mode a significant growth driver in the global pharmacovigilance services market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
According to the latest pharmacovigilance market analysis, North America held the largest share during the forecast period. Stringent regulatory requirements from agencies such as the FDA and Health Canada, increasing demand for post-market surveillance, and the adoption of advanced technologies such as AI and automation for faster ADR detection are some of the leading factors boosting pharmacovigilance industry share.
Additionally, North America's high technology adoption and sophisticated healthcare infrastructure enhance the region's dominance. The use of AI and data analytics within pharmacovigilance processes improves ADR reporting and signal detection, further strengthening the region's position.
Furthermore, the rising prevalence of chronic diseases necessitates continuous drug safety monitoring, contributing to market growth. Increased patient involvement in reporting ADRs via the internet also helps expand the knowledge base of drug safety.
Accenture, IQVIA Inc., Cognizant, Linical, ArisGlobal, ITClinical, ICON plc., TAKE Solutions Limited, Parexel International (MA) Corporation, Wipro, United BioSource LLC, Ergomed Group, Quanticate and others are some of the leading key players operating in the Pharmacovigilance industry.
Each of these players have been have been profiled in the pharmacovigilance market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Size in 2024 | US$ 8.3 Bn |
| Forecast Value in 2035 | US$ 19.4 Bn |
| CAGR | 7.9% |
| Forecast Period | 2025-2035 |
| Historical Data Available for | 2020-2023 |
| Quantitative Units | US$ Bn |
| Pharmacovigilance Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 8.3 Bn in 2024.
It was projected to cross US$ 19.4 Bn by the end of 2035.
Increased drug consumption and surge in clinical trials and outsourcing trends in pharma.
It is projected to advance at a CAGR of 7.9% from 2025 to 2035.
North America was the dominant region in 2024.
Accenture, IQVIA Inc., Cognizant, Linical, ArisGlobal , ITClinical, ICON plc., TAKE Solutions Limited, Parexel International (MA) Corporation, Wipro, United BioSource LLC, Ergomed Group, Quanticate and others.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pharmacovigilance Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pharmacovigilance Market Analysis and Forecast, 2020 to 2035
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Overview of Government Initiatives in Safe Medicine Use
5.2. Rate of Adverse Drug Reactions By Key Region/Countries
5.3. Regulatory Scenario by Region/Country
5.4. Role of Pharmacovigilance during Drug Development Process
5.5. Comparative Analysis of Report used in Pharmacovigilance
5.6. Funding and Investments
5.7. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
5.8. PORTER’s Five Forces Analysis
5.9. PESTEL Analysis
5.10. Value Chain Analysis
6. Global Pharmacovigilance Market Analysis and Forecast, by Phase
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Phase, 2020 to 2035
6.3.1. Pre-clinical
6.3.2. Phase I
6.3.3. Phase II
6.3.4. Phase III
6.3.5. Phase IV
6.4. Market Attractiveness Analysis, by Phase
7. Global Pharmacovigilance Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type, 2020 to 2035
7.3.1. Spontaneous Reporting
7.3.2. Targeted Reporting
7.3.3. Cohort Event Monitoring
7.3.4. Epidemiological Studies
7.3.5. Post-Marketing Surveillance
7.4. Market Attractiveness Analysis, by Type
8. Global Pharmacovigilance Market Analysis and Forecast, by Delivery Mode
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Delivery Mode, 2020 to 2035
8.3.1. In-house
8.3.2. Contract Outsourcing
8.4. Market Attractiveness Analysis, by Delivery Mode
9. Global Pharmacovigilance Market Analysis and Forecast, by Therapeutic Area
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Therapeutic Area, 2020 to 2035
9.3.1. Oncology
9.3.2. Neurology
9.3.3. Cardiology
9.3.4. Respiratory Systems
9.3.5. Autoimmune Diseases
9.3.6. Others
9.4. Market Attractiveness Analysis, by Therapeutic Area
10. Global Pharmacovigilance Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2020 to 2035
10.3.1. Pharmaceutical & Biotechnology Companies
10.3.2. Contract Research Organizations (CROs)
10.3.3. Others
10.4. Market Attractiveness Analysis, by End-user
11. Global Pharmacovigilance Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2020 to 2035
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Region
12. North America Pharmacovigilance Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Phase, 2020 to 2035
12.2.1. Pre-clinical
12.2.2. Phase I
12.2.3. Phase II
12.2.4. Phase III
12.2.5. Phase IV
12.3. Market Value Forecast, by Type, 2020 to 2035
12.3.1. Spontaneous Reporting
12.3.2. Targeted Reporting
12.3.3. Cohort Event Monitoring
12.3.4. Epidemiological Studies
12.3.5. Post-Marketing Surveillance
12.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
12.4.1. In-house
12.4.2. Contract Outsourcing
12.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
12.5.1. Oncology
12.5.2. Neurology
12.5.3. Cardiology
12.5.4. Respiratory Systems
12.5.5. Autoimmune Diseases
12.5.6. Others
12.6. Market Value Forecast, by End-user, 2020 to 2035
12.6.1. Pharmaceutical & Biotechnology Companies
12.6.2. Contract Research Organizations (CROs)
12.6.3. Others
12.7. Market Value Forecast, by Country, 2020 to 2035
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Phase
12.8.2. By Type
12.8.3. By Delivery Mode
12.8.4. By Therapeutic Area
12.8.5. By End-user
12.8.6. By Country
13. Europe Pharmacovigilance Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Phase, 2020 to 2035
13.2.1. Pre-clinical
13.2.2. Phase I
13.2.3. Phase II
13.2.4. Phase III
13.2.5. Phase IV
13.3. Market Value Forecast, by Type, 2020 to 2035
13.3.1. Spontaneous Reporting
13.3.2. Targeted Reporting
13.3.3. Cohort Event Monitoring
13.3.4. Epidemiological Studies
13.3.5. Post-Marketing Surveillance
13.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
13.4.1. In-house
13.4.2. Contract Outsourcing
13.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
13.5.1. Oncology
13.5.2. Neurology
13.5.3. Cardiology
13.5.4. Respiratory Systems
13.5.5. Autoimmune Diseases
13.5.6. Others
13.6. Market Value Forecast, by End-user, 2020 to 2035
13.6.1. Pharmaceutical & Biotechnology Companies
13.6.2. Contract Research Organizations (CROs)
13.6.3. Others
13.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
13.7.1. Germany
13.7.2. UK
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Phase
13.8.2. By Type
13.8.3. By Delivery Mode
13.8.4. By Therapeutic Area
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Pharmacovigilance Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Phase, 2020 to 2035
14.2.1. Pre-clinical
14.2.2. Phase I
14.2.3. Phase II
14.2.4. Phase III
14.2.5. Phase IV
14.3. Market Value Forecast, by Type, 2020 to 2035
14.3.1. Spontaneous Reporting
14.3.2. Targeted Reporting
14.3.3. Cohort Event Monitoring
14.3.4. Epidemiological Studies
14.3.5. Post-Marketing Surveillance
14.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
14.4.1. In-house
14.4.2. Contract Outsourcing
14.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
14.5.1. Oncology
14.5.2. Neurology
14.5.3. Cardiology
14.5.4. Respiratory Systems
14.5.5. Autoimmune Diseases
14.5.6. Others
14.6. Market Value Forecast, by End-user, 2020 to 2035
14.6.1. Pharmaceutical & Biotechnology Companies
14.6.2. Contract Research Organizations (CROs)
14.6.3. Others
14.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
14.7.1. China
14.7.2. Japan
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Phase
14.8.2. By Type
14.8.3. By Delivery Mode
14.8.4. By Therapeutic Area
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Pharmacovigilance Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Phase, 2020 to 2035
15.2.1. Pre-clinical
15.2.2. Phase I
15.2.3. Phase II
15.2.4. Phase III
15.2.5. Phase IV
15.3. Market Value Forecast, by Type, 2020 to 2035
15.3.1. Spontaneous Reporting
15.3.2. Targeted Reporting
15.3.3. Cohort Event Monitoring
15.3.4. Epidemiological Studies
15.3.5. Post-Marketing Surveillance
15.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
15.4.1. In-house
15.4.2. Contract Outsourcing
15.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
15.5.1. Oncology
15.5.2. Neurology
15.5.3. Cardiology
15.5.4. Respiratory Systems
15.5.5. Autoimmune Diseases
15.5.6. Others
15.6. Market Value Forecast, by End-user, 2020 to 2035
15.6.1. Pharmaceutical & Biotechnology Companies
15.6.2. Contract Research Organizations (CROs)
15.6.3. Others
15.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Phase
15.8.2. By Type
15.8.3. By Delivery Mode
15.8.4. By Therapeutic Area
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Pharmacovigilance Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Phase, 2020 to 2035
16.2.1. Pre-clinical
16.2.2. Phase I
16.2.3. Phase II
16.2.4. Phase III
16.2.5. Phase IV
16.3. Market Value Forecast, by Type, 2020 to 2035
16.3.1. Spontaneous Reporting
16.3.2. Targeted Reporting
16.3.3. Cohort Event Monitoring
16.3.4. Epidemiological Studies
16.3.5. Post-Marketing Surveillance
16.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
16.4.1. In-house
16.4.2. Contract Outsourcing
16.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
16.5.1. Oncology
16.5.2. Neurology
16.5.3. Cardiology
16.5.4. Respiratory Systems
16.5.5. Autoimmune Diseases
16.5.6. Others
16.6. Market Value Forecast, by End-user, 2020 to 2035
16.6.1. Pharmaceutical & Biotechnology Companies
16.6.2. Contract Research Organizations (CROs)
16.6.3. Others
16.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Phase
16.8.2. By Type
16.8.3. By Delivery Mode
16.8.4. By Therapeutic Area
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2024)
17.3. Company Profiles
17.3.1. Accenture
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategies
17.3.1.5. Recent Developments
17.3.2. IQVIA Inc.
17.3.2.1. Company Overview
17.3.2.2. Financial Overview
17.3.2.3. Product Portfolio
17.3.2.4. Business Strategies
17.3.2.5. Recent Developments
17.3.3. Cognizant
17.3.3.1. Company Overview
17.3.3.2. Financial Overview
17.3.3.3. Product Portfolio
17.3.3.4. Business Strategies
17.3.3.5. Recent Developments
17.3.4. Linical
17.3.4.1. Company Overview
17.3.4.2. Financial Overview
17.3.4.3. Product Portfolio
17.3.4.4. Business Strategies
17.3.4.5. Recent Developments
17.3.5. ArisGlobal
17.3.5.1. Company Overview
17.3.5.2. Financial Overview
17.3.5.3. Product Portfolio
17.3.5.4. Business Strategies
17.3.5.5. Recent Developments
17.3.6. ITClinical
17.3.6.1. Company Overview
17.3.6.2. Financial Overview
17.3.6.3. Product Portfolio
17.3.6.4. Business Strategies
17.3.6.5. Recent Developments
17.3.7. ICON plc.
17.3.7.1. Company Overview
17.3.7.2. Financial Overview
17.3.7.3. Product Portfolio
17.3.7.4. Business Strategies
17.3.7.5. Recent Developments
17.3.8. TAKE Solutions Limited
17.3.8.1. Company Overview
17.3.8.2. Financial Overview
17.3.8.3. Product Portfolio
17.3.8.4. Business Strategies
17.3.8.5. Recent Developments
17.3.9. Parexel International (MA) Corporation
17.3.9.1. Company Overview
17.3.9.2. Financial Overview
17.3.9.3. Product Portfolio
17.3.9.4. Business Strategies
17.3.9.5. Recent Developments
17.3.10. Wipro
17.3.10.1. Company Overview
17.3.10.2. Financial Overview
17.3.10.3. Product Portfolio
17.3.10.4. Business Strategies
17.3.10.5. Recent Developments
17.3.11. United BioSource LLC
17.3.11.1. Company Overview
17.3.11.2. Financial Overview
17.3.11.3. Product Portfolio
17.3.11.4. Business Strategies
17.3.11.5. Recent Developments
17.3.12. Ergomed Group
17.3.12.1. Company Overview
17.3.12.2. Financial Overview
17.3.12.3. Product Portfolio
17.3.12.4. Business Strategies
17.3.12.5. Recent Developments
17.3.13. Quanticate
17.3.13.1. Company Overview
17.3.13.2. Financial Overview
17.3.13.3. Product Portfolio
17.3.13.4. Business Strategies
17.3.13.5. Recent Developments
List of Tables
Table 01: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
Table 02: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
Table 03: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
Table 04: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
Table 05: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 06: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Region, 2020 to 2035
Table 07: North America - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country, 2020 to 2035
Table 08: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
Table 09: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
Table 10: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
Table 11: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
Table 12: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 13: Europe - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020 to 2035
Table 14: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
Table 15: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
Table 16: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
Table 17: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
Table 18: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 19: Asia Pacific - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020 to 2035
Table 20: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
Table 21: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
Table 22: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
Table 23: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
Table 24: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 25: Latin America - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020 to 2035
Table 26: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
Table 27: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
Table 28: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
Table 29: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
Table 30: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
Table 31: Middle East & Africa - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020 to 2035
Table 32: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
Table 33: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
Table 34: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
Table 35: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
Table 36: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
List of Figures
Figure 01: Global Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
Figure 02: Global Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
Figure 03: Global Pharmacovigilance Market Revenue (US$ Mn), by Pre-clinical, 2020 to 2035
Figure 04: Global Pharmacovigilance Market Revenue (US$ Mn), by Phase I, 2020 to 2035
Figure 05: Global Pharmacovigilance Market Revenue (US$ Mn), by Phase II, 2020 to 2035
Figure 06: Global Pharmacovigilance Market Revenue (US$ Mn), by Phase III, 2020 to 2035
Figure 07: Global Pharmacovigilance Market Revenue (US$ Mn), by Phase v, 2020 to 2035
Figure 08: Global Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
Figure 09: Global Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 10: Global Pharmacovigilance Market Revenue (US$ Mn), by Spontaneous Reporting, 2020 to 2035
Figure 11: Global Pharmacovigilance Market Revenue (US$ Mn), by Targeted Reporting, 2020 to 2035
Figure 12: Global Pharmacovigilance Market Revenue (US$ Mn), by Cohort Event Monitoring, 2020 to 2035
Figure 13: Global Pharmacovigilance Market Revenue (US$ Mn), by Epidemiological Studies, 2020 to 2035
Figure 14: Global Pharmacovigilance Market Revenue (US$ Mn), by Post-Marketing Surveillance, 2020 to 2035
Figure 15: Global Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
Figure 16: Global Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
Figure 17: Global Pharmacovigilance Market Revenue (US$ Mn), by In-house, 2020 to 2035
Figure 18: Global Pharmacovigilance Market Revenue (US$ Mn), by Contract Outsourcing, 2020 to 2035
Figure 19: Global Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 20: Global Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 21: Global Pharmacovigilance Market Revenue (US$ Mn), by Oncology, 2020 to 2035
Figure 22: Global Pharmacovigilance Market Revenue (US$ Mn), by Neurology, 2020 to 2035
Figure 23: Global Pharmacovigilance Market Revenue (US$ Mn), by Cardiology, 2020 to 2035
Figure 24: Global Pharmacovigilance Market Revenue (US$ Mn), by Respiratory Systems, 2020 to 2035
Figure 25: Global Pharmacovigilance Market Revenue (US$ Mn), by Autoimmune Diseases, 2020 to 2035
Figure 26: Global Pharmacovigilance Market Revenue (US$ Mn), by Others, 2020 to 2035
Figure 27: Global Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
Figure 28: Global Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 29: Global Pharmacovigilance Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2020 to 2035
Figure 30: Global Pharmacovigilance Market Revenue (US$ Mn), by Contract Research Organizations (CROs), 2020 to 2035
Figure 31: Global Pharmacovigilance Market Revenue (US$ Mn), by Others 2020 to 2035
Figure 32: Global Pharmacovigilance Market Value Share Analysis, By Region, 2024 and 2035
Figure 33: Global Pharmacovigilance Market Attractiveness Analysis, By Region, 2025 to 2035
Figure 34: North America - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 35: North America - Pharmacovigilance Market Value Share Analysis, by Country, 2024 and 2035
Figure 36: North America - Pharmacovigilance Market Attractiveness Analysis, by Country, 2025 to 2035
Figure 37: North America Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
Figure 38: North America Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
Figure 39: North America Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
Figure 40: North America Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 41: North America Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
Figure 42: North America Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
Figure 43: North America Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 44: North America Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 45: North America Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
Figure 46: North America Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 47: Europe - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 48: Europe - Pharmacovigilance Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 49: Europe - Pharmacovigilance Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 50: Europe Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
Figure 51: Europe Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
Figure 52: Europe Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
Figure 53: Europe Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 54: Europe Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
Figure 55: Europe Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
Figure 56: Europe Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 57: Europe Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 58: Europe Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
Figure 59: Europe Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 60: Asia Pacific - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 61: Asia Pacific - Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
Figure 62: Asia Pacific - Pharmacovigilance Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
Figure 63: Asia Pacific Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
Figure 64: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
Figure 65: Asia Pacific Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
Figure 66: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 67: Asia Pacific Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
Figure 68: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
Figure 69: Asia Pacific Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 70: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 71: Asia Pacific Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
Figure 72: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 73: Latin America - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 74: Latin America - Pharmacovigilance Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 75: Latin America - Pharmacovigilance Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 76: Latin America Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
Figure 77: Latin America Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
Figure 78: Latin America Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
Figure 79: Latin America Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 80: Latin America Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
Figure 81: Latin America Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
Figure 82: Latin America Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 83: Latin America Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 84: Latin America Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
Figure 85: Latin America Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
Figure 86: Middle East & Africa - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
Figure 87: Middle East & Africa - Pharmacovigilance Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
Figure 88: Middle East & Africa - Pharmacovigilance Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
Figure 89: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
Figure 90: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
Figure 91: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
Figure 92: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
Figure 93: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
Figure 94: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
Figure 95: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
Figure 96: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
Figure 97: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
Figure 98: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pharmacovigilance Market
